Aventis expects 25% revenue growth
Aventis Pharma, the Indian subsidiary of French drugmaker Sanofi-Aventis, is expecting a growth of 25% in its revenue in the current calendar year.business Updated: Dec 01, 2010 22:29 IST
Aventis Pharma, the Indian subsidiary of French drugmaker Sanofi-Aventis, is expecting a growth of 25% in its revenue in the current calendar year.
“We have grown by 30% till September this year and hope to end the current year with a overall growth rate of 25%,” said Shailesh Ayyangar, MD-India and vice president- south Asia, global operations.
“We will build capacities in rural areas and expect one-third of the overall sales of the company in India to come from rural markets in 2011,” said Ayyangar.
The company will also launch Combiflam painkiller cream in the the Indian market in January 2011. Currently, it sells 160 crore tablets of Combiflam in India every year.
First Published: Dec 01, 2010 22:28 IST